Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.32 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ANPEP | P15144 | 2/20 | 0.30 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1891743 | 0.79 | MMP2 (0.36) | ADRB2ADRB1ADRB3ALDH1A1CASP3 | |
| SCHEMBL1882948 | 0.78 | ADRB2 (0.39) | ADRB2ADRB1ADRB3ALDH1A1CASP3 | |
| SCHEMBL1891000 | 0.78 | ADRB2 (0.39) | ADRB2ADRB1ADRB3ALDH1A1CASP3 | |
| SCHEMBL3886307 | 0.78 | ADRB2 (0.38) | ADRB2ADRB1ADRB3ALDH1A1CASP3 | |
| SCHEMBL3882871 | 0.78 | ADRB2 (0.38) | ADRB2ADRB1ADRB3ALDH1A1CASP3 | |
| SCHEMBL1886218 | 0.78 | ADRB2 (0.38) | ADRB2ADRB1ADRB3ALDH1A1CASP3 | |
| SCHEMBL1890780 | 0.77 | NAAA (0.37) | ADRB2ADRB1ADRB3ALDH1A1 | |
| SCHEMBL1881697 | 0.77 | ALDH1A1 (0.35) | ADRB2ADRB1ADRB3ALDH1A1CASP3 | |
| SCHEMBL1885832 | 0.75 | ADRB2 (0.37) | ADRB2ADRB1ADRB3ALDH1A1MMP1 | |
| SCHEMBL1886547 | 0.74 | ADRB2 (0.43) | ADRB2ADRB1ADRB3ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935686-B2 | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use | XENOPORT, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090124582-A1 | Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use | XENOPORT, INC. (US) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124582-A1 | Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use | APEH, AASDHPPT, AGPS | ADRB2 4345/4885ADRB1 3993/4885ADRB3 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.